Krystal Biotech, Inc. Share Price & Technical Analysis
KRYS · $299.5 (-1.57%)
Healthcare / Biotechnology
$299.5
-1.57%
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrop…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
14% return in May, 7% avg return in past 3 year May month.
24% return in 2026, 50% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | 0% | -3% | 1% | 14% | – | – | – | – | – | – | – | 24% |
| 25 | 0% | 14% | 1% | -5% | -25% | 9% | 11% | -3% | 19% | 12% | 10% | 14% | 58% |
| 24 | -10% | 42% | 10% | -14% | 5% | 13% | 13% | -7% | -6% | -5% | 14% | -20% | 38% |
| 23 | 4% | -2% | -2% | 5% | 41% | -1% | 12% | -4% | -7% | 1% | -11% | 18% | 55% |
| 22 | -16% | 7% | 6% | -10% | -3% | 10% | 11% | -5% | 0% | 7% | 0% | 2% | 9% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$9.14B
P/E ratio
41.44
52W high
$319.5
52W low
$123.0
Volume
1,62,219
Beta
0.49
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Krystal Biotech, Inc. share price today?
- Krystal Biotech, Inc. (KRYS) last traded around $299.5 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KRYS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KRYS. Download the app for real-time alerts.
- How can I analyze Krystal Biotech, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.